Alcohol Use Disorder Treatment Market to Reach US$2.46 Billion by 2035 as Treatment Engagement Becomes the New Commercial Battleground

The global alcohol use disorder treatment market was valued at US$1.36 billion in 2025 and is projected to reach US$2.46 billion by 2035, expanding at a CAGR of 6.1% from 2026 to 2035. The most important commercial shift is not simply the availability of another medicine. It is the redesign of how people enter, stay in and pay for treatment.

Alcohol use disorder is one of the most under-treated chronic health conditions. Many patients do not seek help until an emergency admission, liver-related complication, workplace issue or psychiatric crisis forces contact with the health system. This makes the treatment market structurally different from many other therapeutic categories: the addressable patient population is much larger than the patient population that reaches a prescription, counseling program or specialist center.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/alcohol-use-disorder-treatment-market?kailas

Multidisciplinary treatment accounted for an estimated 48% of market revenue in 2025, representing about US$653 million. This segment brings together clinical assessment, withdrawal management, counseling, behavioral support, relapse prevention and social-care coordination. Its large share reflects the recurring service requirement for moderate-to-severe cases. However, the traditional residential and specialist-center model faces pressure from capacity constraints, high out-of-pocket costs and the reluctance of many patients to attend a visibly addiction-focused facility.

That pressure is opening a more practical route to market: treatment initiated through primary care, emergency departments, mental-health practices, liver clinics and telehealth providers. The commercial advantage of these channels is discretion and convenience. Their weakness is continuity. Screening alone has limited value when the patient leaves without a same-day prescription, scheduled follow-up or confirmed referral. Providers that combine screening, medication initiation, counseling and follow-up are better positioned than platforms that offer one isolated consultation.

Medication represented an estimated 37% of 2025 market revenue, supported by naltrexone, acamprosate, disulfiram and withdrawal-management medicines. Oral therapies continue to dominate because they are familiar, comparatively accessible and easy to initiate in outpatient settings. Yet adherence remains a persistent limitation. A daily tablet can be clinically appropriate but commercially fragile when a patient disengages after the first few weeks.

Long-acting injectable naltrexone addresses part of that problem by reducing the daily pill burden and giving clinicians a documented administration event. Its adoption, however, depends on prior authorization, product inventory, trained staff, medical-benefit billing and follow-up scheduling. This is why a clinically differentiated therapy can still struggle if the delivery model is not built around provider workflow and reimbursement.

The next generation of competition is moving toward patient selection and measurable behavior change. Abstinence remains an important treatment outcome, but it does not reflect the goal of every patient who is willing to seek care. Reduced heavy-drinking days, lower craving and sustained engagement are gaining greater commercial relevance because they can make treatment more acceptable to people unwilling or unable to commit to immediate abstinence.

This shift could widen recruitment for clinical trials and broaden the treated population. It also raises the evidence threshold. Payers and health systems will expect proof that lower alcohol consumption translates into fewer hospital visits, reduced liver-related complications, improved mental-health outcomes or lower total care costs. A reduction in drinking that cannot demonstrate durable health-system value will be difficult to commercialize at scale.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/alcohol-use-disorder-treatment-market?kailas

North America held an estimated 44% share of global revenue in 2025, equal to nearly US$598 million, with the United States contributing about US$496 million. The region benefits from established specialty networks, telehealth infrastructure and access to long-acting formulations. At the same time, fragmented payer coverage remains a major conversion risk. Product developers entering the U.S. market need to plan for diagnosis, drug acquisition, administration, behavioral support and retention as one integrated access pathway.

Europe offers a different opportunity profile. Publicly funded systems and established addiction services create a foundation for treatment access, but national reimbursement processes and country-specific evidence requirements can slow adoption. In Asia-Pacific, large untreated populations create long-term potential, though underdiagnosis, stigma and uneven specialist capacity mean that low-cost medicines and community-linked outpatient services may outperform premium, facility-dependent models.

Company Profiles and Competitive Developments

Alkermes plc remains a major commercial participant through VIVITROL, its extended-release injectable naltrexone product for alcohol dependence and opioid dependence. The monthly administration model reduces daily adherence burden and is supported by existing provider familiarity in addiction care. However, the product must compete with lower-cost oral options and navigate clinician-administered drug reimbursement. Alkermes' 2025 company reporting continues to position VIVITROL as a core proprietary product, although brand revenue is not specific to alcohol use disorder alone.

Adial Pharmaceuticals, Inc. is developing AD04, an investigational therapy designed for genetically selected patients with alcohol use disorder who drink heavily. Its approach combines low-dose ondansetron with a companion genetic test intended to identify patients more likely to respond. Adial's strategy is notable because it targets people seeking to reduce alcohol consumption rather than relying exclusively on abstinence-led care. During 2025 and 2026, the company advanced Phase III planning, worked on manufacturing readiness and pursued regulatory engagement around clinically meaningful outcomes beyond abstinence.

Clearmind Medicine Inc. is developing CMND-100, an oral, non-hallucinogenic neuroplastogen-derived candidate intended to address alcohol consumption and craving. In August 2026, the company reported that an independent safety board supported advancement of its FDA-regulated Phase I/II study into patients with moderate-to-severe alcohol use disorder after the healthy-volunteer stage met its primary safety objective. The program remains investigational, but it highlights the growing interest in therapies that aim to alter addiction-related neural pathways without requiring prolonged supervised psychedelic sessions.

BrainsWay Ltd. launched a multicenter clinical trial of its Deep TMS 360 system for alcohol use disorder. The study is evaluating whether noninvasive brain stimulation can reduce heavy-drinking days and craving in patients with moderate-to-severe disease. BrainsWay's model differs from pharmaceutical competition because commercialization would run through trained clinical sites rather than conventional pharmacy channels. Alcohol use disorder is not a cleared indication for the system, and the opportunity depends on positive trial results, regulatory authorization, clinician training and payer coverage.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=alcohol-use-disorder-treatment-market?kailas

Additional Benefits:
✅ Get Interactive Dashboard Access (With No Additional Cost)
✅ Three months of analyst support to answer queries related to the report.

The alcohol use disorder treatment market is therefore moving away from a medicine-only framework. Future value will accrue to companies that can link clinical efficacy with a workable care pathway: early identification, a realistic patient goal, reliable reimbursement, simple treatment delivery and follow-up strong enough to prevent relapse from becoming treatment abandonment.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

DataM Intelligence's report provides detailed analysis of market size, treatment type, disorder type, delivery route, end-user settings, country opportunity and pipeline positioning. Request a sample to assess treatment segments, supplier positioning, target accounts, channel models and the near-term revenue pockets shaping alcohol use disorder treatment through 2035.

This release was published on openPR.